New combination treatments in the management of asthma: Focus on fluticasone/vilanterol

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Despite the 2007 National Asthma Education and Prevention Program Expert Panel 3 guidelines for the treatment of uncontrolled asthma, many patients with poorly controlled asthma still continue to tax the health care system. Controlling asthma symptoms and preventing acute exacerbations have been the foundation of care. Using long-term controller treatments such as inhaled corticosteroids (ICS) and inhaled long-acting beta2-agonists (LABAs) is a common approach. While patient responses to recommended pharmacotherapy may vary, poor adherence to therapy also contributes to poor asthma control. A once-daily combination inhaler, such as fluticasone furoate, an ICS, in combination with vilanterol, a LABA, offers increased convenience and potential improved adherence, which should result in enhanced clinical outcomes and reduced exacerbations. The ICS/LABA combination inhaler of fluticasone furoate and vilanterol is currently approved in the United States for use in the maintenance of chronic obstructive pulmonary disease and to reduce exacerbations. This paper reviews the expanding literature on the efficacy of fluticasone furoate and vilanterol in treating asthma.

Original languageEnglish (US)
Pages (from-to)77-83
Number of pages7
JournalJournal of Asthma and Allergy
Issue number7
DOIs
StatePublished - May 3 2014

Fingerprint

Asthma
Adrenal Cortex Hormones
Nebulizers and Vaporizers
Therapeutics
Chronic Obstructive Pulmonary Disease
Fluticasone
vilanterol
Maintenance
Guidelines
Delivery of Health Care
Education
Drug Therapy
fluticasone furoate

Keywords

  • Asthma treatments
  • Inhaled Corticosteroids (ICS)
  • Long-Acting Beta2-Agonist (LABA)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

New combination treatments in the management of asthma : Focus on fluticasone/vilanterol. / Tan, Laren D.; Chan, Andrew; Albertson, Timothy E.

In: Journal of Asthma and Allergy, No. 7, 03.05.2014, p. 77-83.

Research output: Contribution to journalArticle

@article{79d0f519f3f441a0b643ba325981099d,
title = "New combination treatments in the management of asthma: Focus on fluticasone/vilanterol",
abstract = "Despite the 2007 National Asthma Education and Prevention Program Expert Panel 3 guidelines for the treatment of uncontrolled asthma, many patients with poorly controlled asthma still continue to tax the health care system. Controlling asthma symptoms and preventing acute exacerbations have been the foundation of care. Using long-term controller treatments such as inhaled corticosteroids (ICS) and inhaled long-acting beta2-agonists (LABAs) is a common approach. While patient responses to recommended pharmacotherapy may vary, poor adherence to therapy also contributes to poor asthma control. A once-daily combination inhaler, such as fluticasone furoate, an ICS, in combination with vilanterol, a LABA, offers increased convenience and potential improved adherence, which should result in enhanced clinical outcomes and reduced exacerbations. The ICS/LABA combination inhaler of fluticasone furoate and vilanterol is currently approved in the United States for use in the maintenance of chronic obstructive pulmonary disease and to reduce exacerbations. This paper reviews the expanding literature on the efficacy of fluticasone furoate and vilanterol in treating asthma.",
keywords = "Asthma treatments, Inhaled Corticosteroids (ICS), Long-Acting Beta2-Agonist (LABA)",
author = "Tan, {Laren D.} and Andrew Chan and Albertson, {Timothy E}",
year = "2014",
month = "5",
day = "3",
doi = "10.2147/JAA.S39625",
language = "English (US)",
pages = "77--83",
journal = "Journal of Asthma and Allergy",
issn = "1178-6965",
publisher = "Dove Medical Press Ltd.",
number = "7",

}

TY - JOUR

T1 - New combination treatments in the management of asthma

T2 - Focus on fluticasone/vilanterol

AU - Tan, Laren D.

AU - Chan, Andrew

AU - Albertson, Timothy E

PY - 2014/5/3

Y1 - 2014/5/3

N2 - Despite the 2007 National Asthma Education and Prevention Program Expert Panel 3 guidelines for the treatment of uncontrolled asthma, many patients with poorly controlled asthma still continue to tax the health care system. Controlling asthma symptoms and preventing acute exacerbations have been the foundation of care. Using long-term controller treatments such as inhaled corticosteroids (ICS) and inhaled long-acting beta2-agonists (LABAs) is a common approach. While patient responses to recommended pharmacotherapy may vary, poor adherence to therapy also contributes to poor asthma control. A once-daily combination inhaler, such as fluticasone furoate, an ICS, in combination with vilanterol, a LABA, offers increased convenience and potential improved adherence, which should result in enhanced clinical outcomes and reduced exacerbations. The ICS/LABA combination inhaler of fluticasone furoate and vilanterol is currently approved in the United States for use in the maintenance of chronic obstructive pulmonary disease and to reduce exacerbations. This paper reviews the expanding literature on the efficacy of fluticasone furoate and vilanterol in treating asthma.

AB - Despite the 2007 National Asthma Education and Prevention Program Expert Panel 3 guidelines for the treatment of uncontrolled asthma, many patients with poorly controlled asthma still continue to tax the health care system. Controlling asthma symptoms and preventing acute exacerbations have been the foundation of care. Using long-term controller treatments such as inhaled corticosteroids (ICS) and inhaled long-acting beta2-agonists (LABAs) is a common approach. While patient responses to recommended pharmacotherapy may vary, poor adherence to therapy also contributes to poor asthma control. A once-daily combination inhaler, such as fluticasone furoate, an ICS, in combination with vilanterol, a LABA, offers increased convenience and potential improved adherence, which should result in enhanced clinical outcomes and reduced exacerbations. The ICS/LABA combination inhaler of fluticasone furoate and vilanterol is currently approved in the United States for use in the maintenance of chronic obstructive pulmonary disease and to reduce exacerbations. This paper reviews the expanding literature on the efficacy of fluticasone furoate and vilanterol in treating asthma.

KW - Asthma treatments

KW - Inhaled Corticosteroids (ICS)

KW - Long-Acting Beta2-Agonist (LABA)

UR - http://www.scopus.com/inward/record.url?scp=84903631188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903631188&partnerID=8YFLogxK

U2 - 10.2147/JAA.S39625

DO - 10.2147/JAA.S39625

M3 - Article

AN - SCOPUS:84903631188

SP - 77

EP - 83

JO - Journal of Asthma and Allergy

JF - Journal of Asthma and Allergy

SN - 1178-6965

IS - 7

ER -